NCT06459180 2026-03-13
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
30 trialsNCT05239741 2026-03-10
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT04230187 2026-03-05
TRIBE-C
Sun Yat-sen University
Phase 3 Recruiting
NCT05677490 2026-03-04
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06951503 2026-03-04
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Akeso
Phase 3 Recruiting
NCT04215731 2026-03-03
FOBEAR
Sun Yat-sen University
Phase 3 Recruiting
NCT05863195 2026-03-02
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06998940 2026-02-20
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06958328 2026-02-02
LAP100
NRG Oncology
Phase 3 Recruiting
NCT07375563 2026-01-29
NB-NK-2026
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT07265674 2026-01-23
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3 Recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT06644781 2026-01-12
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Daiichi Sankyo
Phase 3 Recruiting
NCT05008809 2025-12-12
AIO-KRK-0418
Charite University, Berlin, Germany
Phase 3 Recruiting
NCT06733038 2025-12-08
AtezoTRIBE2
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT04776655 2025-10-02
LIBImAb
Azienda USL Reggio Emilia - IRCCS
Phase 3 Recruiting
NCT06490536 2025-08-29
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3 Recruiting
NCT06250972 2025-08-07
PTCA199-11
Fudan University
Phase 3 Recruiting
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT04861558 2025-05-30
EFFIPEC
Uppsala University
Phase 3 Recruiting
NCT04415853 2025-05-18
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Sunshine Lake Pharma Co., Ltd.
Phase 3 Recruiting
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT04927780 2024-08-28
PREOPANC-3
Erasmus Medical Center
Phase 3 Recruiting
NCT06509126 2024-07-19
IMPROVE-2
National Cancer Institute, Naples
Phase 3 Recruiting
NCT05954078 2024-05-20
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
Fudan University
Phase 3 Recruiting
NCT06194734 2024-03-07
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06123494 2024-01-16
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT05794971 2023-05-15
RIDER
Sun Yat-sen University
Phase 3 Recruiting
NCT05201430 2022-03-04
RCNAC
Fudan University
Phase 3 Recruiting